CCR research lays foundation for FDA approval of CAR T cell therapy Yescarta


Decades ago, the use of chimeric antigen receptor (CAR)-expressing T cells as an effective form of immunotherapy was a speculative idea. In 2010, a breakthrough clinical trial conducted by Steven Rosenberg, M.D., Ph.D., and his clinical team showed that CAR T cells recognizing the CD19 receptor were useful in the treatment of some types of B-cell malignancies. The research foundation laid by CCR investigators paved the way for the recent U.S. Food and Drug Administration (FDA) approval of axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or treatment-resistant large B-cell lymphoma. Yescarta is just one of several therapies that have sprung from cell transfer immunotherapy work done by Dr. Rosenberg and others at NCI. CCR researchers continue to vigorously pursue every avenue of research in this field in pursuit of even more promising outcomes and hope for patients with cancer. Read more about the development of Yescarta…

Summary Posted: 10/2017